Clinical Research Directory

Inclusion Criteria: * Female age 65 and older * Staging: 1. Patients enrolled prior to surgery: Diagnosis of clinical T1-2N0, ER+, HER2-negative, invasive breast cancer as determined by treating physician. DCIS or LCIS may be present with invasive cancer. 2. Patients enrolled after surgery: pT1-2NX, or pT1-2N0, ER+, HER2-negative, invasive breast cancer. DCIS or LCIS may be present with invasive cancer. * Plan to undergo lumpectomy within 3 months of study registration, or underwent lumpectomy within 60 days of study registration (without sentinel node biopsy) * Patients in whom lymph nodes are palpable and not suspicious who are found to be nodal tumor-free by nodal core needle biopsy are permitted, but those with biopsy-proven nodal metastases are excluded Exclusion Criteria: * Patients with diagnosis of ductal or lobular carcinoma in situ * Patients with diagnosis of inflammatory breast cancer * Patients who have undergone neoadjuvant chemotherapy for current primary breast cancer (past treatments for other cancers are acceptable) * Patients planning to have mastectomy or had a mastectomy of the ipsilateral breast * Prior history of ipsilateral (invasive or DCIS) breast cancer * Diagnosis of clinical T3 or T4 breast cancer